Federal Xarelto Lawsuits Progress with Issuance of New Order Governing Plaintiffs’ Fact Sheets
New York, New York (PRWEB) May 18, 2015 -- Hundreds of federally-filed Xarelto lawsuits (http://www.xareltolawsuit2015.com/) continue to move forward in a federal multidistrict litigation now underway in U.S. District Court, Eastern District of Louisiana. According to a Pretrial Order dated May 4, 2015, all plaintiffs who have individual cases pending in the proceeding are now required to complete a Plaintiff Fact Sheet. Among other things, the Order stipulates that a signed and verified Fact Sheet, along with all signed and dated Authorizations and responsive documents be submitted to Defendants within 60 days of the Order’s entry, or within 60 day’s of a lawsuit’s filing or transfer to the Eastern District of Louisiana, whichever is longer. (In Re: Xarelto Products Liability Litigation, No. 2592)
“Plaintiff Fact Sheets serve as an efficient way to obtain initial disclosures regarding a claimant’s medical background and other issues relevant to their cases. Our Firm is representing federal Xarelto lawsuit plaintiffs, and we are pleased that discovery is moving forward in the multidistrict litigation,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered a life-threatening internal bleeding episode, a stroke, deep vein thrombosis or pulmonary embolism due to their use of this blood thinner.
Xarelto Litigation
Court documents indicate that at least 434 Xarelto lawsuits have been filed in the federal litigation currently underway in the Eastern District of Louisiana. More than 200 similar complaints are pending in a mass tort program underway in Pennsylvania’s Philadelphia Court of Common Pleas. (In Re: Xarelto Litigation, Case ID 150102349) All of these lawsuits similarly accuse the manufacturers of Xarelto of wrongly marketing the blood thinner as an improvement over warfarin, an anticoagulant that has been on the market for decades. Among other things, plaintiffs point out that internal bleeding associated with warfarin can be stopped via the administration of vitamin K, while there currently exists no approved reversal agent for Xarelto bleeding.
Xarelto was cleared for sale by the U.S. Food & Drug Administration in 2011, and is now approved for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. A black box warning on the Xarelto label includes information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*
Xarelto patients who allegedly experienced uncontrollable internal bleeding or life-threatening complications related to its use may be entitled to compensation. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf, FDA, March 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.xareltolawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author
Sandy A. Liebhard, Xarelto Lawsuit Claims Center, http://www.xareltolawsuit2015.com/, +1 800-511-5092, [email protected]
Share this article